In human melanoma cell lines, loss of expression of the endogenous cyclin-dependent kinase inhibitor (CDKN2A), encoding for two distinct potent tumor suppressor proteins, p16INK4a and p14ARF, has shown to correlate with sensitivity to palbociclib; while Rb loss correlated with resistance (57). Here, CDKN2A is linked to melanoma.